Stockbroker tips from ShareCast

Broker snap: Glaxo backed ahead of asthma drug meet

An independent clinical trial has identified GlaxoSmithKline's Advair as the best drug for kids with asthma when 'first-line' therapy fails, prompting Panmure Gordon to repeat its 'buy' stance.

The medical journal New England Journal of Medicine (NEJM) says a component of Advair represents the most likely add-on therapy for children whose asthma is not controlled by inhaled corticosteroids (ICS).

Panmure recommends snapping up stock ahead of a Food & Drug Administration (FDA) advisory committee meeting on the use of asthma drugs on 10 March.

"GSK has undergone the majority of its patent expiries and emerged strongly, and can now focus on growth. It has a strong pipeline of products, led by Benlysta for lupus and which could reach the market in 2010 and provide a significant source of upside," says the broker.

"We believe that most of the risks are adequately reflected in the price," it added, keeping its £14 target price.

Stockbroker tips: Most read

Broker tips: BT, Misys, GAME
Fri 03 February 2012 11:27
Broker tips: ARM, Whitbread, Premier Oil
Mon 30 January 2012 11:25
Broker tips: Glencore, Shell, 888
Mon 06 February 2012 12:44
Broker tips: N. Brown, Aveva, Max Petroleum
Fri 27 January 2012 11:31
Broker tips: ARM, Afren, Heritage Oil...
Tue 31 January 2012 11:52

Deal shares from just
£5.95 per deal
Find out more »

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

Market latest

FTSE 100 | FTSE 250 | All Share

FTSE 100	5,895.47	+0.33%
FTSE 250	11,234.57	+0.65%
FTSE All Share	3,046.11	+0.39%
Dow Jones	12,890.46	+0.05%
NASDAQ	2,927.23	+0.39%
Xetra DAX	6,788.80	+0.59%
Paris CAC 40	3,424.71	+0.43%
Nikkei 225	8,984.84	-0.19%
Hang Seng	20,969.41	-0.19%